#EVENTDATE#, #EVENTTIME# #EVENTTIMEZONESHORT#
Title: “Tirzepatide Mediated Weight Loss: Insights from Preclinical Pharmacology Studies”
Speakers: Ricardo J. Samms, Ph.D. and Minrong Ai, Ph.D.
Tirzepatide is a dual GIP and GLP-1 receptor agonist engineered by Lilly scientists. In a Phase 2b clinical trial in T2DM patients, Tirzepatide demonstrated superior weight loss compared to that of a GLP-1 receptor agonist (dulaglutide). While much is known about how GLP-1 reduces caloric intake, the mechanism(s) by which GIP functions alone and in combination with GLP-1 to cause weight loss remains to be elucidated. Here, in preclinical models of obesity, we provide an update on our efforts to determine the contribution of GIP to the weight loss efficacy of Tirzepatide.